APA (7th ed.) Citation

Pouyiourou, M., Kraft, B., Wohlfromm, T., Stahl, M., Kubuschok, B., Löffler, H., . . . Krämer, A. (2023). Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: A phase II trial. Nature Communications, 14, . https://doi.org/10.1038/s41467-023-42400-5

Chicago Style (17th ed.) Citation

Pouyiourou, Maria, et al. "Nivolumab and Ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: A Phase II Trial." Nature Communications 14 (2023). https://doi.org/10.1038/s41467-023-42400-5.

MLA (9th ed.) Citation

Pouyiourou, Maria, et al. "Nivolumab and Ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: A Phase II Trial." Nature Communications, vol. 14, 2023, https://doi.org/10.1038/s41467-023-42400-5.